CHRNA3 Antibody

What is CHRNA3 and what is its molecular function?

CHRNA3, also known as NACHRA3, LNCR2, and PAOD2, is a member of the nicotinic acetylcholine receptor family that plays important roles in calcium regulation, neuronal development, and cognitive functions . It encodes an alpha-type subunit containing characteristic adjacent cysteine residues and forms pentameric complexes with both alpha and beta subunits . After binding acetylcholine, the receptor undergoes an extensive conformational change affecting all subunits, leading to the opening of an ion-conducting channel across the plasma membrane . This makes CHRNA3 a ligand-gated ion channel that plays a critical role in neurotransmission .

Functionally, CHRNA3 interacts with proteins such as CHRNB2 (nicotinic acetylcholine receptor beta-2 subunit) to modulate synaptic strength and integration in the central nervous system . This interaction exemplifies how CHRNA3 participates in complex neuronal signaling pathways that regulate various physiological processes.

What applications are CHRNA3 antibodies suitable for?

CHRNA3 antibodies have been validated for multiple research applications with varying dilution requirements:

Most commercially available CHRNA3 antibodies are rabbit polyclonal antibodies that show reactivity with human and mouse samples . For optimal results, researchers should titrate these antibodies in their specific testing systems, as the optimal dilution may be sample-dependent .

What is the expected molecular weight of CHRNA3 in Western blotting?

When performing Western blot analysis, researchers should note that while the calculated molecular weight of CHRNA3 is approximately 57 kDa , the observed molecular weight typically ranges between 50-55 kDa . This discrepancy may be due to post-translational modifications, alternative splicing, or protein degradation.

When validating antibody specificity, the predicted band size is 57 kDa . For example, in Western blot analyses with HeLa cells at 40 μg protein load, using a 1/600 dilution of anti-CHRNA3 antibody (with Goat anti-Rabbit IgG-H&L (HRP) at 1/10000 dilution as secondary antibody), the expected exposure time is approximately 1 minute for visualization .

How should researchers optimize antigen retrieval for CHRNA3 immunohistochemistry?

For immunohistochemical analysis of CHRNA3, antigen retrieval methodology significantly impacts staining quality. Current evidence suggests:

The preferred method for CHRNA3 detection in tissue sections is antigen retrieval with TE buffer at pH 9.0 . Alternatively, citrate buffer at pH 6.0 may be used, though potentially with reduced signal intensity . This is particularly important when working with formalin-fixed, paraffin-embedded tissues, where protein crosslinking can mask epitopes.

For example, when performing immunohistochemical analysis of paraffin-embedded human ovarian cancer tissue, an antibody dilution of 1/10 has been successfully used . Different tissue types may require optimization of both the antigen retrieval method and antibody dilution to balance signal intensity with background reduction.

What validation approaches should be employed when working with CHRNA3 antibodies?

Robust validation of CHRNA3 antibodies is essential for reliable research outcomes. Recommended validation approaches include:

• Knockout/Knockdown Validation: Several publications have validated CHRNA3 antibodies using KD/KO approaches . This represents the gold standard for antibody validation, as it confirms specificity through the absence of signal in samples lacking the target protein.

• Multiple Application Validation: Confirm antibody performance across different applications. CHRNA3 antibodies from reliable sources have been validated in Western blot (4 publications), immunohistochemistry (1 publication), immunofluorescence (2 publications), and flow cytometry (1 publication) .

• Cross-Species Reactivity Testing: While most CHRNA3 antibodies show reactivity with human and mouse samples, specific reactivity should be verified when working with other species .

• Peptide Competition Assays: These can help confirm specificity, particularly for antibodies raised against synthetic peptides within specific amino acid regions of CHRNA3 (e.g., aa 50-100) .

How can researchers effectively study CHRNA3 genetic variants?

CHRNA3 genetic variants have significant research value due to their associations with nicotine addiction, COPD, and lung cancer. Effective study approaches include:

• SNP Genotyping: TaqMan® SNP Genotyping Assays run on real-time PCR systems are effective for analyzing key CHRNA3 polymorphisms . Key SNPs of interest include rs1051730, rs8034191, rs6495309, and rs16969968, which have shown significant associations with disease states .

• Population Considerations: Research has shown different association patterns between CHRNA3 variants and disease across populations. For example, rs1051730 shows the most significant association to COPD in non-Asians , while rs6495309 shows significant associations with both COPD and lung cancer in southern and eastern Chinese populations .

• Multi-SNP Analysis: Because multiple polymorphisms influence brain function and nicotine addiction, comprehensive analysis should include various SNPs. The T allele variant of SNP rs1051730 has been strongly associated with cigarettes smoked per day and nicotine dependence rates , while homozygous CC alleles at rs6495309 increase COPD risk, and heterozygous alleles (CT/CC) show association with lung cancer risk .

What are common troubleshooting strategies for CHRNA3 antibody experiments?

When facing challenges with CHRNA3 antibody experiments, consider these strategies:

• Non-specific Western Blot Bands: If observing multiple bands, optimize antibody dilution (try 1:1000-1:6000 range) , increase washing steps, and consider using different blocking agents. Remember that the observed molecular weight (50-55 kDa) may differ from the calculated weight (57 kDa) .

• Weak IHC Signal: For paraffin-embedded tissues, compare TE buffer (pH 9.0) versus citrate buffer (pH 6.0) for antigen retrieval . Adjust antibody concentration (recommended range: 1:500-1:2000 for IHC) . Extended primary antibody incubation (overnight at 4°C) may improve signal.

• Background in Immunofluorescence: Implement additional blocking steps, test both paraformaldehyde and methanol fixation methods, and ensure proper permeabilization for this transmembrane protein.

• Sample Preparation Issues: For optimal protein extraction, use buffers containing detergents appropriate for membrane proteins, as CHRNA3 is a transmembrane ion channel protein .

What storage and handling recommendations ensure optimal antibody performance?

To maintain CHRNA3 antibody functionality:

How does CHRNA3 research contribute to understanding nicotine addiction?

CHRNA3 has demonstrated significant relevance to nicotine addiction research:

In 2008, Thorgeirsson et al. established a crucial connection between CHRNA3 and nicotine addiction, specifically identifying a strong association between the T allele variant of SNP rs1051730 and the quantity of cigarettes smoked per day . Their research also demonstrated that individuals with this variant exhibit higher rates of nicotine dependence .

Multiple subsequent studies have confirmed the connection between SNP rs1051730 and nicotine dependence . This genetic association provides a mechanistic explanation for individual differences in susceptibility to nicotine addiction, as CHRNA3 encodes a nicotinic acetylcholine receptor subunit that directly interacts with nicotine in the brain.

Researchers investigating nicotine addiction should consider incorporating CHRNA3 genotyping in their experimental design, as these genetic variants may significantly influence behavioral and physiological responses to nicotine across both human and animal models.

What is the significance of CHRNA3 in respiratory disease research?

CHRNA3 has emerged as an important factor in respiratory diseases:

• COPD Association: Meta-analyses by Cui et al. positively linked 4 SNPs from the CHRNA3/5 locus to chronic obstructive pulmonary disease (COPD), with rs1051730 showing the most significant association to COPD in non-Asian populations .

• Lung Cancer Risk: Multiple studies have confirmed connections between CHRNA3 polymorphisms and lung cancer susceptibility . Yang et al. (2012) found that individuals with the heterozygous alleles (CT/CC) at SNP rs6495309 showed increased risk for lung cancer in southern and eastern Chinese populations .

• Mechanistic Insights: Zhang et al. (2011) revealed a susceptibility connection between rs1051730 and COPD specifically related to airway obstruction and parenchyma destruction, providing insights into the pathophysiological mechanisms .

These findings highlight the importance of CHRNA3 in respiratory disease pathogenesis beyond its role in nicotine addiction, suggesting direct effects on respiratory tissue that may be independent of smoking behavior.

What emerging techniques are advancing CHRNA3 research?

Cutting-edge approaches for CHRNA3 research include:

• CRISPR/Cas9 Gene Editing: Creation of precise CHRNA3 knockout or knockin models allows for detailed functional studies of specific variants associated with disease risk.

• Single-Cell Transcriptomics: Analysis of CHRNA3 expression at single-cell resolution reveals cell type-specific roles in neural circuits and cancer microenvironments.

• Improved Antibody Technologies: Development of more specific monoclonal antibodies targeting different CHRNA3 epitopes enhances detection sensitivity and specificity across applications .

• Combined Genomic and Proteomic Approaches: Integration of CHRNA3 genotyping with protein expression analysis provides more comprehensive understanding of how genetic variants influence protein function and disease risk .

How can researchers integrate CHRNA3 findings with broader research contexts?

To maximize the impact of CHRNA3 research:

• Multi-System Analysis: Consider CHRNA3's roles across neural, respiratory, and cancer biology when designing research protocols, as findings in one system may inform understanding in others.

• Translational Approaches: Combine findings from genetic association studies with functional experiments using validated antibodies to bridge population-level findings with molecular mechanisms .

• Related Gene Consideration: When interpreting CHRNA3 antibody results, consider interactions with other nicotinic receptor subunits, particularly CHRNB2, which forms functional complexes with CHRNA3 .

• Biomarker Development: Explore the potential of CHRNA3 expression or genetic variants as biomarkers for disease risk stratification, particularly in lung cancer and COPD patient populations .